PREVALENCE OF FATIGUE AND IMPACT ON QUALITY OF LIFE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS: the VITAL study.

BMC Urol · 2019 · PMC6796370 · PMID 31619215

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The proportion of patients with clinically significant fatigue (BFI item 3 score ≥ 5) was lower among patients with ≥3 months of abiraterone acetate plus prednisone treatment than in those receiving HT (25.6% versus 41.3%), although this difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.